Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

Porcine circovirus type 2 (PCV2) infection can lead to porcine circovirus-associated disease (PCVAD), causing great economic losses to the global swine industry. Conventional vaccination programs are a major measure in the prevention and control of this disease. Currently, there are 5 commercially available PCV2 vaccines in the international market and 10 kinds commercially available PCV2 vaccines in the Chinese market that confer good efficacy against this virus by alleviating clinicopathological manifestations and enhancing growth performance in pigs. In addition, diverse experimental PCV2 vaccines with protective efficiency have been developed, including attenuated chimeric, nucleic acid, subunit, multivalent, and viral-vectored vaccines. These experimental vaccines have been shown to be relatively effective in improving the efficiency of pig production and simplifying prevention procedures. Adjuvants can be used to promote vaccines with higher protective immunity. Herein, we review the application of multiple commercial vaccines over the years and research advances in experimental vaccines, which provide the possibility for the development of superior vaccines to successfully prevent and control PCV2 infection in the future.

Automated summary

Porcine circovirus type 2 (PCV2) infection causes significant economic losses to the global swine industry. Vaccination, both commercially available and experimental, has shown efficacy in preventing and controlling PCV2-associated disease. Adjuvants can enhance the protective immunity of vaccines. Further research and development of superior vaccines are needed for effective prevention and control of PCV2 infection.